The fund's exposure to Danish pharmaceutical firm Zealand Pharma A/S hit 12.1%, according to its February factsheet, surpassing the 10% limit imposed on UCITS vehicles. Four Graphs explaining silver Zealand Pharma is involved in the production and design of diabetes and obesity medications, a corner of the healthcare market which has seen a huge surge in investment in the wake of Novo Nordisk's Ozempic medication becoming a cult product for weight loss. The company's shares had historically traded at around 200 DKK (£22.92) per share, but last month it experienc...
To continue reading this article...
Join now
Login
Read more on investmentweek.co.uk